

Gambro

theralite

HIGH CUT-OFF MEMBRANE

SPECIALIZED DIALYZER FOR THE REMOVAL OF FREE LIGHT CHAIN (FLC) PROTEINS

The Gambro THERALITE dialyzer, featuring the proprietary High Cut-Off (HCO) membrane, was developed for the removal of free light chain (FLC) proteins, that are overproduced in patients with Multiple Myeloma and can cause renal failure.^{1,2}

EFFECTIVE MEMBRANE DESIGN

- THERALITE dialyzer's HCO membrane is characterized by its large and uniform pore size^{1,11}
- High permeability for substances in the molecular weight range of up to 45 kDa³
- Effective retention of larger proteins with molecular weights greater than 60 kDa, such as clotting factors⁷
- Manufactured to the same quality standards as the POLYFLUX and REVACLEAR dialyzers
- A key adjunctive treatment in Multiple Myeloma Kidney therapy^{1,4,5,9,12}



TYPICAL PATIENT PROFILE: PATIENTS THAT WOULD BENEFIT FROM FLC REMOVAL, SUCH AS MULTIPLE MYELOMA KIDNEY PATIENTS

Gambro THERALITE Dialyzer

SPECIFICATIONS	THERALITE
Measured according to EN 1283/ISO 8637	
UF coef. In vitro [ml/(h*mmHg)]	52
Priming volume in vitro [ml]	140
Flow resistance [mmHg] / max. values Q _B = 200-500 ml/min, UF = 0 ml blood compartment	<190
Max. transmembrane pressure [mmHg]	300
Range of blood flow rates [ml/min]	200–500
Range of dialyrate flow rate [ml/min]	300–800
Residual blood volume [ml]	<5 ml
Fluid volumes needed for priming and rinsing [ml]	≥1000

Membrane

Effective membrane area [m ²]	2.1
Wall thickness [μm]	50
Inner diameter [μm]:	215
Sterilization agent	Steam
Sterile barrier	Medical grade paper

Components

Membrane	PAES/PVP
Potting material	Polyurethane (PUR)
Housing and caps	Polycarbonate (PC)
O-rings	Silicone rubber (SIR)
Protective caps	Polypropylene (PP)

Dialysis fluid connectors and blood connectors are designed according to EN 1283/ISO 8637



1. Boschetti-de-Fierro A, et al. *Int J Artif Organs* 2013; 36:455–463.
2. Hutchison CA, et al. *Nat Rev Nephrol* 2012; 8:43–51.
3. Hutchison CA, et al. *J Am Soc Nephrol* 2007; 18:886–895.
4. Hutchison CA, et al. *Clin J Am Soc Nephrol* 2009; 4:745–754.
5. Bachmann U, et al. *NDT plus* 2008; 1:106–108.
6. Zannetti BA, et al. *Am J Hematol* 2015; 90:647–652.
7. Villa G, et al. *Blood Purif* 2014; 38:167–173.
8. Cantaluppi V, et al. *Nephrol Dial Transplant* 2013; 28:i415–i427.
9. Dahal K, et al. *Clin Kidney J* 2013; 79:318–322.
10. Li Cavoli G, et al. *Clin Kidney J* 2012; 5: 80.
11. Waikowicz Z. *Med Sci Monit* 2013; 19:984–992.
12. Hutchinson, C, et al. *Nephrol Dial Transplant* 2013; 27:3823–3828.

For the safe and proper use of the Theralite (High-Cut Off Dialyzer) refer to contraindications, warnings and precautions, adverse events and the complete directions for use.

Baxter Corporation
7125 Mississauga Road
Mississauga, Ontario L5N 0C2

PERFORMANCE	THERALITE			
Hemodialysis (HD) Q ₀ = 500 ml/min, UF = 0 ml/min Measured acc. to EN 1283 / ISO 8637, clearance in vitro [ml/min] ± 10%				
Q_B [ml/min]	200	300	400	500
Urea	199	286	349	390
Phosphate	195	269	320	354
Myoglobin	126	146	160	170
Sieving coefficient in vitro Measured acc. to EN 1283/ISO 8637 (± 20%); Bovine plasma, protein level 60g/l, 37°C				
Vitamin B12	1.0			
Inulin	1.0			
Myoglobin	0.95			
Albumin	0.2			

Baxter, Gambro, HCO, Polyflux, Revaclear and Theralite are trademarks of Baxter International Inc. or its subsidiaries.